These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9639252)

  • 1. Penetration of dynorphin 1-13 across the blood-brain barrier.
    Turner TD; Browning JL; Widmayer MA; Baskin DS
    Neuropeptides; 1998 Apr; 32(2):141-9. PubMed ID: 9639252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo transport of a dynorphin-like analgesic peptide, E-2078, through the blood-brain barrier: an application of brain microdialysis.
    Terasaki T; Deguchi Y; Sato H; Hirai K; Tsuji A
    Pharm Res; 1991 Jul; 8(7):815-20. PubMed ID: 1681528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An HPLC/RIA method for dynorphin A1-13 and its main metabolites in human blood.
    Müller S; Ho B; Gambus P; Millard W; Hochhaus G
    J Pharm Biomed Anal; 1997 Sep; 16(1):101-9. PubMed ID: 9447557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of dynorphin A 1-13 in human blood and plasma.
    Müller S; Hochhaus G
    Pharm Res; 1995 Aug; 12(8):1165-70. PubMed ID: 7494829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of peptidase inhibitors on anti-nociceptive action of dynorphin-(1-8) in rats.
    Kitamura K; Akahori K; Yano H; Iwao K; Oka T
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):273-8. PubMed ID: 10731039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for pore-like opening of the blood-brain barrier following forebrain ischemia in rats.
    Preston E; Foster DO
    Brain Res; 1997 Jun; 761(1):4-10. PubMed ID: 9247060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific binding and clearance of [3H]dynorphin (1-13) in the perfused rat lung: an application of the multiple-indicator dilution method.
    Sato H; Terasaki T; Tsuji A
    J Pharm Pharmacol; 1990 Dec; 42(12):879-82. PubMed ID: 1983155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynorphin A (2-17) attenuates the unconditioned but not the conditioned effects of opiate withdrawal in the rat.
    Shippenberg TS; Funada M; Schutz CG
    Psychopharmacology (Berl); 2000 Sep; 151(4):351-8. PubMed ID: 11026742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioids modulate post-ischemic progression in a rat model of stroke.
    Kao TK; Ou YC; Liao SL; Chen WY; Wang CC; Chen SY; Chiang AN; Chen CJ
    Neurochem Int; 2008 May; 52(6):1256-65. PubMed ID: 18294735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for dynorphin-A as a neurotransmitter in rat hippocampus.
    Chavkin C; Bakhit C; Bloom FE
    Life Sci; 1983; 33 Suppl 1():13-6. PubMed ID: 6141483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interspecies comparison of in vitro plasma degradation of dynorphin A 1-13.
    Müller S; Dunker R; Hochhaus G
    Pharmazie; 1996 Aug; 51(8):581-5. PubMed ID: 8794468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease.
    Klintenberg R; Andrén PE
    J Mass Spectrom; 2005 Feb; 40(2):261-70. PubMed ID: 15706626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The degradation of dynorphin A in brain tissue in vivo and in vitro.
    Young EA; Walker JM; Houghten R; Akil H
    Peptides; 1987; 8(4):701-7. PubMed ID: 2888101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine-dependent rats.
    Al-Fayoumi SI; Brugos B; Arya V; Mulder E; Eppler B; Mauderli AP; Hochhaus G
    Pharm Res; 2004 Aug; 21(8):1450-6. PubMed ID: 15359581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorptive-mediated endocytosis of a dynorphin-like analgesic peptide, E-2078 into the blood-brain barrier.
    Terasaki T; Hirai K; Sato H; Kang YS; Tsuji A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):351-7. PubMed ID: 2571724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antinociceptive effects of dynorphin peptides in a model of inflammatory pain.
    Beyer A; Schäfer M; Stein C
    Pain; 1997 Apr; 70(2-3):141-7. PubMed ID: 9150287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential passage of [14C]sucrose and [3H]inulin across rat blood-brain barrier after cerebral ischemia.
    Preston E; Webster J
    Acta Neuropathol; 2002 Mar; 103(3):237-42. PubMed ID: 11907803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilized dynorphin derivatives for modulating antinociceptive activity in morphine tolerant rats: effect of different routes of administration.
    Brugos B; Arya V; Hochhaus G
    AAPS J; 2004 Dec; 6(4):e36. PubMed ID: 15760101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The permeation of dynorphin A 1-6 across the blood brain barrier and its effect on bovine brain microvessel endothelial cell monolayer permeability.
    Sloan CD; Audus KL; Aldrich JV; Lunte SM
    Peptides; 2012 Dec; 38(2):414-7. PubMed ID: 23046728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMM-H004, A New Coumarin Derivative, Improved Focal Cerebral Ischemia via Blood-Brain Barrier Protection in Rats.
    Niu F; Song XY; Hu JF; Zuo W; Kong LL; Wang XF; Han N; Chen NH
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2065-2073. PubMed ID: 28669655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.